CAR-T細胞療法市場、標的抗原別、治療用途別、地域別- 規模、シェア、展望、機会分析、2022年～2030年

CAR-T細胞療法は、免疫T細胞を使ってがんを破壊する免疫療法の一種です。CAR-T細胞療法は、T細胞の遺伝子を改変することから、細胞性遺伝子治療とも呼ばれています。CAR-T細胞療法では、白血球破砕法（leukapheresis）という方法でT細胞を体外に取り出します。抽出したT細胞に、特定のキメラ抗原受容体（CAR）の遺伝子を付加して改変することから、CAR-T細胞と呼ばれます。CAR-T細胞は、特定のキメラ抗原受容体（CAR）の遺伝子を導入して改変した後、増殖させ、体内に注入されます。CAR-T細胞療法は、特定の種類のがんと闘うために、さまざまなタイプが作られています。CAR-T細胞は、患者さんごとにカスタマイズされ、血液中に注入されます。CAR-T細胞療法は、がんと闘うための新しい遺伝子療法として使用されます。特定のがんに対する様々なCAR-T細胞療法の安全性と有効性を研究するために、様々な臨床および前臨床試験が行われています。また、米国疾病対策予防センター（CDC）による教育キャンペーンなど、複数の政府ががんに対する認識を広めるための取り組みを行っています。

市場力学

製品の承認など、市場における主要なプレーヤーによる有機的な戦略の採用が増加しており、予測期間中の市場成長を促進すると予想されます。例えば、2022年5月、世界ヘルスケア企業の1つであるNovartis AG.は、再発または難治性の濾胞性リンパ腫の成人患者の治療用としてKymriah（tisagenlecleucel）CAR-T細胞療法の米国食品医薬品局承認を取得しました。今回の承認は、第II相臨床試験において、68％の奏効率で評価されたことによります。

本調査の主な特徴

• 本レポートでは、世界のCAR-T細胞療法市場を詳細に分析し、2021年を基準年とした予測期間（2022-2030年）の市場規模および年平均成長率（CAGR％）を示しています。
• 異なるセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスを説明します。
• また、市場促進要因、抑制要因、機会、新製品の発売または承認、市場動向、地域別の展望、主要企業が採用する競合戦略など、重要な考察を提供しています。
• 世界のCAR-T細胞療法市場における主要企業のプロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、財務実績、戦略といったパラメータに基づいて紹介しています。
• この調査の一部としてカバーされている主要企業は、Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
• このレポートからの洞察は、企業のマーケティング担当者や経営陣が、将来の製品の発売、タイプのアップグレード、市場の拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にするでしょう。
• CAR-T細胞療法の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。
• 利害関係者は、世界のCAR-T細胞療法市場の分析に使用される様々な戦略マトリクスを通じて、意思決定を容易にすることができます。

目次

第1章 調査目的と前提条件

• 調査目的
• 前提条件
• 略語の説明

第2章 市場の展望

• レポート内容
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場スナップショット：標的抗原別
  • 市場スナップショット：治療用途別
  • 市場スナップショット：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• インパクト分析
• 市場動向
• 最近の動向
• 買収とパートナーシップのシナリオ
• 法規制シナリオ
• パイプライン分析
• PEST分析
• ポーターズ分析

第4章 CAR-T細胞療法の世界市場-COVID-19インパクト分析

• 全体的なインパクト
• 需給への影響
• COVID-19の市場に対するインパクト

第5章 CAR-T細胞療法の世界市場：標的抗原別、2017年～2030年

• CD19
• BCMA
• HER2
• GD2
• CD20
• CD22
• CD30
• CD33
• HER1
• その他（CLDN18など）

第6章 CAR-T細胞療法の世界市場：治療用途別、2017年～2030年

• 急性リンパ性白血病
• 慢性リンパ性白血病
• びまん性大細胞型B細胞リンパ腫（DLBCL）
• 濾胞性リンパ腫（Follicular Lymphoma
• マントル細胞リンパ腫
• 多発性骨髄腫
• 神経膠芽腫（グリオブラストーマ
• 肉腫
• 神経芽腫
• 急性骨髄性白血病
• 乳がん
• 膵臓がん
• 肝細胞がん
• 大腸がん
• その他（胃がんなど）

第7章 CAR-T細胞療法の世界市場：地域別、2017年～2030年

• 北米
• 米国
• カナダ
• ラテンアメリカ
• ブラジル
• メキシコ
• アルゼンチン
• その他のラテンアメリカ地域
• 欧州
• 英国
• ドイツ
• イタリア
• フランス
• スペイン
• ロシア
• その他の欧州地域
• アジア太平洋地域
• 中国
• インド
• 日本
• ASEAN
• オーストラリア
• 韓国
• その他アジア太平洋地域
• 中東地域
• GCC
• イスラエル
• その他の中東地域
• アフリカ
• 北アフリカ
• 中央アフリカ
• 南アフリカ

第8章 競合情勢

• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• CARsgenTherapeutics Co.,Ltd
• Aurora Biopharma
• Legend Biotech
• Gilead Sciences, Inc.
• Pfizer Inc.
• bluebird bio, Inc.
• Sorrento Therapeutics, Inc.
• Mustang Bio
• Fate Therapeutics

第9章 セクション

• 調査手法
• 出版社について

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study:

• This report provides in-depth analysis of the global CAR T cell therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global CAR T cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market

Detailed Segmentation:

• Global CAR T Cell Therapy Market, By Targeted Antigen:
  • CD19
  • BCMA
  • HER2
  • GD2
  • CD20
  • CD22
  • CD30
  • CD33
  • HER1
  • Others (CLDN18, etc.)
• Global CAR T Cell Therapy Market, By Therapeutic Application:
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Glioblastoma
  • Sarcoma
  • Neuroblastoma
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others (Gastric Cancer, etc.)
• Global CAR T Cell Therapy Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • CARsgenTherapeutics Co., Ltd
  • Aurora Biopharma
  • Legend Biotech
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • bluebird bio, Inc.
  • Sorrento Therapeutics, Inc.
  • Mustang Bio
  • Fate Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Targeted Antigen
  • Market Snapshot, By Therapeutic Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis
• Porter's Analysis

4. Global CAR T Cell Therapy Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global CAR T Cell Therapy Market, By Targeted Antigen, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• CD19
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• BCMA
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• HER2
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• GD2
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD20
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD22
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD30
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• CD33
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• HER1
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (CLDN18, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global CAR T Cell Therapy Market, By Therapeutic Application, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Acute Lymphocytic Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Chronic Lymphocytic Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Diffuse Large B-cell Lymphoma (DLBCL)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Follicular Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Mantle Cell Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Multiple Myeloma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Glioblastoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Sarcoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Neuroblastoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Acute Myeloid Leukemia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Pancreatic Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hepatocellular Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Gastric Cancer, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global CAR T Cell Therapy Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Targeted Antigen, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Johnson & Johnson Services, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CARsgenTherapeutics Co.,Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aurora Biopharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Legend Biotech
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• bluebird bio, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sorrento Therapeutics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mustang Bio
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Fate Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us